Peter Ueda
Overview
Explore the profile of Peter Ueda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lim C, Simonsson M, Pasternak B, Jernberg T, Edgren G, Ueda P
JACC Cardiovasc Interv
. 2025 Jan;
18(5):637-650.
PMID: 39846914
Background: The aim of the ARC-HBR (Academic Research Consortium for High Bleeding Risk) and PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score definitions...
3.
Coude Adam H, Hajimirsadeghi O, Krantz L, Brismar K, Norhammar A, Ueda P, et al.
BMJ Open
. 2025 Jan;
15(1):e093625.
PMID: 39819959
Purpose: There is limited research on individuals undergoing self-initiated health examinations, and the Werlabs cohort will be a base for such research. Participants: All individuals aged 18 or older who...
4.
Tornhammar P, Julner A, Al Moosawi N, Wicksell E, Lim C, Andersson D, et al.
BMJ Open
. 2024 Nov;
14(11):e085906.
PMID: 39542470
Background: Early in the COVID-19 pandemic, numerous clinical trials were initiated. Although concerns were raised regarding the quality of the trials, the eventual research output yielded from the trials remains...
5.
Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al.
JAMA Intern Med
. 2024 Sep;
184(11):1301-1312.
PMID: 39226030
Importance: Concerns have been raised regarding a link between use of glucagon-like peptide-1 (GLP-1) receptor agonists and increased risk of suicidality and self-harm. Objective: To assess the association between use...
6.
Engstrom A, Soderling J, Hviid A, Eliasson B, Gudbjornsdottir S, Wintzell V, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Jun;
10(5):432-443.
PMID: 38918063
Aims: To assess the comparative cardiovascular and renal effectiveness and safety of empagliflozin vs. dapagliflozin among patients with type 2 diabetes in routine clinical practice. Methods And Results: Cohort study...
7.
Ghaznavi C, Ueda P, Nomura S, Ishikane M, Uno S, Sakamoto H
Sex Transm Infect
. 2024 Jun;
100(6):371-380.
PMID: 38871450
Objectives: Approximately half of Japanese men aged 20-49 years have purchased sexual services, but data concerning the use of commercial sex work (CSW) in Japan remain scarce. Methods: We used...
8.
Yari A, Ueda P, Lundman P, Alfredsson J, Ravn-Fischer A, Soderberg S, et al.
Eur J Prev Cardiol
. 2024 Jun;
31(15):1890-1897.
PMID: 38842486
Aims: To estimate the proportion eligible for lipid-lowering therapy (LLT) when using the systemic coronary risk estimation 2 (SCORE2) on apparently healthy individuals. Methods And Results: Individuals aged 50-64 years...
9.
Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjornsdottir S, Jonasson C, et al.
BMJ
. 2024 Apr;
385:e078225.
PMID: 38683947
Objective: To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer. Design: Scandinavian cohort study. Setting: Denmark, Norway, and Sweden, 2007-21....
10.
Engstrom A, Wintzell V, Melbye M, Svanstrom H, Eliasson B, Gudbjornsdottir S, et al.
Hepatology
. 2023 Dec;
79(6):1401-1411.
PMID: 38085855
Background And Aims: Clinical trials suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may have beneficial effects on NAFLD, but the impact on hard hepatic end points is unknown. We assessed...